Critical effect sizes in toxicological risk assessment: A comprehensive and critical evaluation

Environmental Toxicology and Pharmacology

Volumn 10, Issue 1-2, 2001, Pages 33-52

  Dekkers, Susan ^a   De Heer, Cees ^a   Rennen, Monique A J ^a  

^a TNO   (Netherlands)

Author keywords

Benchmark modelling; Critical effect size; Risk assessment

Indexed keywords

ARTICLE; CONTROLLED STUDY; HUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; TOXICOLOGICAL PARAMETERS;

EID: 0034993101     PISSN: 13826689     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1382-6689(01)00068-0     Document Type: Article

References (58)

1. Comparison of quantitative dose response modelling approaches for evaluating foetal weight changes in segment II developmental toxicity studies
2. Dose-response assessment for developmental toxicity. II. Comparison of generic Benchmark dose estimates with no observed adverse effect levels
3. Dose-response assessment for developmental toxicity. III. Statistical models
4. Benchmark dose analysis of developmental toxicity in rats exposed to boric acid
5. Calculation of Benchmark doses for reproductive and developmental toxicity observed after exposure to isopropanol
6. Negative selection in hepatic tumour promotion in relation to cancer risk assessment
7. Estimating Benchmark concentrations and other noncancer endpoints in epidemiology studies
8. Benchmark dose workshop: Criteria for use of a Benchmark dose to estimate a reference dose
9. Alternatives for a risk assessment on chronic noncancer effects from oral exposure to trichloroethylene
10. Symposium overview improvements in quantitative noncancer risk assessment. Sponsored by the risk assessment speciality section of the society of toxicology
11. Investigation of the potential impact of Benchmark dose and pharmacokinetic modelling in noncancer risk assessment
12. Comparing the results of a Monte Carlo analysis with EPA's reasonable maximum exposed individual (RMEI): A case study of a former wood treatment site
13. A new method for determining allowable daily intakes
14. Calculation of Benchmark doses from continuous data
15. Reanalysis of dose-response data from the Iraqi methylmercury poisoning episode
16. Influence of prenatal mercury exposure upon scholastic and psychological test performance: Benchmark analysis of a New Zealand cohort
17. The EPA health risk assessment of methylcyclopentadienyl manganese tricarbonyl (MMT)
18. Application of Benchmark dose risk assessment methodology to developmental toxicity: An industrial view
19. A comparison of methods for estimating the Benchmark dose based on overdispersed data from developmental toxicity studies
20. Incidence of developmental defects at the no observed adverse effect level (NOAEL)
21. Risk assessment for neurotoxic effects
22. Risk assessment of nongenotoxic carcinogens based upon cell proliferation/death rates in rodents
23. Procedures for calculating Benchmark doses for health risk assessment
24. Application of the Benchmark method to risk assessment of trichloroethene
25. Non-cancer risk assessment for nickel compounds: Issues associated with dose-response modelling of inhalation and oral exposures
26. Effect of study design on benchmark dose estimates
27. A simulation study of the effect of study design on benchmark dose (BMD) estimates
28. Dose-response assessments for developmental toxicity. IV. Benchmark doses for fetal weight changes
29. A simulation study of the influence of study design on the estimation of benchmark doses for developmental toxicity
30. Reproductive and developmental effects of diethylene and triethylene glycol (methyl-, ethyl-) ethers
31. The application of benchmark dose methodology to data from prenatal developmental toxicity studies
32. Neurotoxicity modelling for risk assessment
33. Intuitive toxicology: Expert and lay judgements of chemical risks
34. Estimation of a chromium inhalation reference concentration using the benchmark dose method: A case study
35. Developmental toxicity of carbendazim: Comparison of no-observed-adverse-effect level and benchmark dose approach
36. Application of a biologically-based RFD estimation method to tetrachlorodibenzo-p-dioxin (TCDD) mediated immune suppression and enzyme induction
37. Characterizing dose-response: I: Critical assessment of the benchmark dose concept
38. Selective vulnerability of dopaminergic systems to industrial chemicals: Risk assessment of related neuroendocrine changes
39. Comparison of BMD with NOAEL and LOAEL values derived from subchronic toxicity studies
40. Comparing alternative approaches to establishing regulatory levels for reproductive toxicants: DBCP as a case study
41. An approach for modelling noncancer dose responses with an emphasis on uncertainty
42. Biologically based, quantitative risk assessment of neurotoxicants
43. Biologically-based dose-response model for neurotoxicity risk assessment
44. A probabilistic approach for deriving acceptable human intake limits and human health risks from toxicological studies: General framework
45. Assessment factors for human health risk assessment: A discussion paper
46. Effect of subchronic 2,3,7,8-tetrachlorodibenzo-p-dioxin exposure on immune system and target gene responses in mice: Calculation of benchmark doses for CYP1A1 and CYP1A2 related enzyme activities